PCA3: A new tool to diagnose prostate cancer (PCa) and a guidance in biopsy decisions. Preliminary report of the UrOP study

Archivio Italiano di Urologia e Andrologia

Volumn 82, Issue 1, 2010, Pages 5-9

  Galasso, Fabio ^a   Giannella, Renato ^a   Bruni, Paola ^c   Giulivo, Rosaria ^c   Barbini, Vittorino Ricci ^d   Disanto, Vincenzo ^e   Leonardi, Rosario ^f   Pansadoro, Vito ^b   Sepe, Giuseppe ^a  

^a Casa di Cura Malzoni Villa Platani ^*  (Italy)

^b Casa di Cura Pio XI   (Italy)

^c Laboratorio di Biodiagnostica Montevergine Malzoni   (Italy)

^d Ospedale di Poggibonsi   (Italy)

^e Casa di Cura S Rita   (Italy)

^f Clinica Basile   (Italy)

Author keywords

Benign Prostatic Hyperplasia (BPH); Digital Rectal Examination (DRE); Prostate Cancer (PCa), biopsy; Prostate cancer gene 3 (PCA3); Prostate Specific Antigen (PSA)

Indexed keywords

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; ONCOGENE; POLYMERASE CHAIN REACTION; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER GENE 3; URINALYSIS; URINE LEVEL;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BIOPSY; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS;

EID: 77953320510     PISSN: 11243562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Catalona WJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324:1156.
2. Loeb S, et al. Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. J Urol 2006; 175:902.
3. Stamey TA, et al. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993; 71:933.
4. Nadler RB, et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995; 154:407-13.
5. Sindhwani P, et al. Prostatitis and serum prostate-specific antigen. Curr Urol Rep 2005; 6:307-12.
6. Bhanot S, et al. Post-biopsy rise in serum PSA. A potential tool for the dynamic evaluation of prostate cancer/prostatic intraepithelial neoplasia (PIN). Cancer Biol Ther 2003; 2:67-70.
7. Oremek GM, et al. Physical activity release prostate-specific antigen (PSA) form the prostate gland into blood and increases serum PSA concentrations. Clin Chem 1996; 42:691-5.
8. Zappa M, et al. Overdiagnosis of prostate carcinoma by screening: an estimated based on the results of the Florence Screening Pilot Study. Ann Oncol 1998; 9: 1297-300.
9. Groskopf J, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006; 52:1089-95.
10. Bussemakers MJG, et al. DD3: A new prostate-specific gene, highly over-expressed in prostate cancer. Cancer Res 1999; 59:5975-9.
11. Karakiewicz PI, et al. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol 2005; 173:1930-4.
12. Walz J, Haese A, Scattoni V, et al. Percent free prostatespecificantigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower. Cancer 2008; 113:2695-703.
13. Chun FK, et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol. 2009 Oct; 56(4):659-67.
14. Nakanishi H, Groskopf J, Fritsche HA, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008; 179:1804-9, discussion 1809-10.
15. Seitz C, et al. Prostate biopsy. Minerva Mol Nefrol 2003; 55:205-18.
16. Haese A, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy Eur Urol 2008 Nov; 54(5):1081-8.
17. Raja J, et al. Current status of transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer. Clin Radiol 2006; 61:142-153.
18. Marks LS, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007; 69:532-5.